Results 71 to 80 of about 214,341 (267)

A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
This study introduces a foundation model‐based biomarker for risk stratification of pathological response in non‐small cell lung cancer. A Vision Mamba super‐resolution model standardizes heterogeneous CT images. A multi‐task Swin Transformer then fine‐tunes a pre‐trained lung foundation model to jointly optimize tumor segmentation and response ...
Yanglan Xu   +10 more
wiley   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai   +12 more
wiley   +1 more source

Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor–Ligand Interactions

open access: yesAdvanced Science, EarlyView.
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim   +8 more
wiley   +1 more source

Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [PDF]

open access: yesJournal of Pharmacy & Pharmacognosy Research
Context: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs.
Precella Silvia   +2 more
doaj   +1 more source

Single‐Cell Reveal GALNT7‐Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan   +11 more
wiley   +1 more source

CauFinder: Steering Cell‐State and Phenotype Transitions by Causal Disentanglement Learning

open access: yesAdvanced Science, EarlyView.
CauFinder combines causal disentanglement modeling and network control to prioritize causal drivers of cell‐state transitions from observational transcriptomic data. The framework separates transition‐relevant signals from spurious associations, nominates intervention targets across biological and disease contexts, and identifies DAAM1 as an actionable
Chengming Zhang   +11 more
wiley   +1 more source

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

open access: yesAdvanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun   +15 more
wiley   +1 more source

PFKFB4 Deubiquitination by USP10 Enhances Fumarate Metabolism to Orchestrate the KDM1A/Rad51 Axis and Confer Radioresistance in Lung Cancer

open access: yesAdvanced Science, EarlyView.
USP10 binds to and stabilizes PFKFB4, enhancing glycolytic ATP production, which activates the urea cycle and elevates fumarate. This inhibits histone demethylase KDM1A, leading to increased H3K4me1 enrichment at the Rad51 promoter and direct activation of Rad51 transcription, which confers lung cancer radioresistance. The PFKFB4 inhibitor 5MPN targets
Yunshang Chen   +7 more
wiley   +1 more source

The impact of artificial intelligence on a multi-omics approach toward predictive biomarkers for non-small cell lung cancer [PDF]

open access: yesExploration of Digital Health Technologies
Over the last four decades, lung cancer has been the leading cause of death in the United States. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and historically, treatment consists of surgical resection, chemotherapy, and/or ...
Brandon Wilkins   +5 more
doaj   +1 more source

Modulation of Lung Adenocarcinoma by Phosphorylated FOXN3‐Mediated Transcriptional Inactivation of p53

open access: yesAdvanced Science, EarlyView.
In non‐tumorous lung tissues, FOXN3 promotes the transcriptional activation of p53 by facilitating its recruitment to target promoters, thereby suppressing lung tumorigenesis through activation of the p53 signaling pathway. Conversely, in lung adenocarcinoma tissues, hyperphosphorylated FOXN3 dissociates from the promoters of p53‐responsive genes and ...
Jinjin Yu   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy